Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Compare healthcare utilization and costs between Medicare beneficiaries with idiopathic pulmonary fibrosis (IPF) receiving pirfenidone or nintedanib. Methods: Retrospective cohort study of Medicare beneficiaries (100% Research Identifiable Files) with IPF who initiated pirfenidone or nintedanib between 15 October 2014 and 31 December 2015. Inverse probability of treatment weighting using propensity scores adjusted for baseline covariates. Outcomes: hospitalization and monthly costs. Results: Hazard and incidence rate ratios (95% CI) for all-cause (0.79 [0.68–0.91]; 0.69 [0.59–0.82]) and respiratory-related (0.80 [0.65–0.97]; 0.71 [0.57–0.90]) hospitalizations favored pirfenidone versus nintedanib. Monthly inpatient costs were lower for pirfenidone versus nintedanib patients; outpatient and pharmacy costs were similar. Conclusion: In patients with IPF, pirfenidone compared with nintedanib has a moderate but significant protective effect on hospitalization, corresponding to lower inpatient costs.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 378(19), 1811–1823 (2018).
2.
Raghu G, Chen S-Y, Yeh W-S et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir. Med. 2(7), 566–572 (2014).
• As data for the epidemiology of idiopathic pulmonary fibrosis (IPF) in the USA is limited, this study is significant as it reports higher incidence and prevalence rates of IPF in people 65 and older in the USA, along with an annually increasing prevalence.
3.
Collard HR, Chen S-Y, Yeh W-S et al. healthcare utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann. Am. Thorac. Soc. 12(7), 981–987 (2015).
• Provides supporting evidence that in the US Medicare population, patients with idiopathic pulmonary fibrosis face substantial healthcare resource utilization and costs.
4.
Meyer KC, Danoff SK, Lancaster LH, Nathan SD. Management of idiopathic pulmonary fibrosis in the elderly patient. Chest 148(1), 242–252 (2015).
5.
Spagnolo P, Tzouvelekis A, Bonella F. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther. Clin. Risk Manag. 11, 359 (2015).
• This article summarizes current therapeutic options for IPF, as well as highlighting the need for a cure and optimized treatment for severe cases of IPF.
6.
Raghu G, Collard HR, Egan JJ et al. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183(6), 788–824 (2011).
7.
Mooney JJ, Raimundo K, Chang E, Broder MS. Hospital cost and length of stay in idiopathic pulmonary fibrosis. J. Med. Econ. 20(5), 518–524 (2017).
8.
Mooney JJ, Raimundo K, Chang E, Broder MS. Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden. BMC Pulm. Med. 17(1), 84 (2017).
9.
Raghu G, Rochwerg B, Zhang Y et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 192(2), e3–e19 (2015).
10.
D`empsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of the antifibrotic medications for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 200(2), 168–174 (2019).
•• This is the first real-world analysis in the US of the clinical effectiveness of pirfenidone and nintedanib. The study found that the medications were associated with a reduced risk of all-cause mortality in IPF compared with an untreated matched cohort; however, it did not compare hospitalizations between drugs.
11.
Ley B, Swigris J, Day B et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196(6), 756–761 (2017).
12.
Richeldi L, du Bois RM, Raghu G et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370(22), 2071–2082 (2014).
13.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46(3), 399–424 (2011).
14.
Pezzi A, Cavo M, Biggeri A, Zamagni E, Nanni O. Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma. BMC Med. Res. Methodol. 16(1), 150 (2016).
• Supports our study's methods as it found that propensity score-based methods are valuable to adjust for imbalances caused by observable covariates in the context of randomized controlled trials. In this case study, introducing propensity scores into a model by inverse probability weighting allowed for increased robustness.
15.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40(5), 373–383 (1987).
16.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45(6), 613–619 (1992).
17.
Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). (2019). www.hcup-us.ahrq.gov/nisoverview.jsp
18.
Pulmonary Care and Research Collaborative, LLC. ILD Centers in the USA. (2020). www.ildcollaborative.org/ild-centers-in-the-usa
19.
Agency for Healthcare Research and Quality. HCUP Chronic Condition Indicator. (2015). www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp
20.
Nau D. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. Pharmacy Quality Alliance, VA, USA (2012).
21.
Lancaster LH, de Andrade JA, Zibrak JD et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 26(146), 170057 (2017).
22.
Bargagli E, Piccioli C, Rosi E et al. Pirfenidone and nintedanib in idiopathic pulmonary fibrosis: real-life experience in an Italian referral centre. Pulmonology 25(3), 149–153 (2019).
•• We found only one other head-to-head real-world study comparing the effectiveness of pirfenidone and nintedanib. While it reported that both antifibrotic drugs were good options for lung function stabilization, neither utilization or cost differences were examined.
23.
Corral M, DeYoung K, Kong AM. Impact of antifibrotic use on healthcare resource use and cost in patients with idiopathic pulmonary fibrosis (IPF) in a commercially insured patient population. Chest 156(Suppl. 4), A1137 (2019).
24.
Carlos WG, Strek ME, Wang TS et al. Treatment of idiopathic pulmonary fibrosis. Ann. ATS 13(1), 115–117 (2016).
25.
Wuyts WA, Wijsenbeek M, Bondue B et al. Idiopathic pulmonary fibrosis: best practice in monitoring and managing a relentless fibrotic disease. Respiration 99(1), 73–82 (2020).
Information & Authors
Information
Published In
Pages: 933 - 943
PubMed: 32851849
Copyright
© 2020 Mitra Corral. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 14 May 2020
Accepted: 30 July 2020
Published online: 27 August 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0084
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Alexander Diamantopoulos, Oliver Pople, Antonia Godman, Evangelos Papastergios, Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use, PharmacoEconomics, 10.1007/s40273-026-01600-9, (2026).
- Siow Yeh Chiew, Mustapha Mohammed, Siew Chin Ong, Economic burden and cost drivers of interstitial lung disease: a systematic review, The European Journal of Health Economics, 10.1007/s10198-025-01836-w, 27, 4, (821-842), (2025).
- Mona Nili, Andrew J. Epstein, Dominic Nunag, Amy Olson, Bijan J Borah, Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients, BMC Pulmonary Medicine, 10.1186/s12890-024-02929-7, 24, 1, (2024).
- Mona Nili, Andrew J. Epstein, Dominic Nunag, Amy Olson, Bijan Borah, Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients, BMC Pulmonary Medicine, 10.1186/s12890-023-02496-3, 23, 1, (2023).
- Vincent Cottin, Paolo Spagnolo, Philippe Bonniaud, Faustine Dalon, Maëva Nolin, Klaus-Uwe Kirchgässler, Eric Van Ganse, Manon Belhassen, Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis, Respiratory Medicine and Research, 10.1016/j.resmer.2022.100951, 83, (100951), (2023).
- Ingrid A. Cox, Barbara de Graaff, Hasnat Ahmed, Julie Campbell, Petr Otahal, Tamera J. Corte, Yuben Moodley, Nicole Goh, Peter Hopkins, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer, The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study, The European Journal of Health Economics, 10.1007/s10198-022-01538-7, 24, 7, (1121-1139), (2022).
- David Singer, Lindsay G S Bengtson, Craig S Conoscenti, Amy J Anderson, Lee Brekke, Sharash S Shetty, Kevin K Brown, Burden of illness in progressive fibrosing interstitial lung disease, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2022.28.8.871, 28, 8, (871-880), (2022).
- Pavo Marijic, Larissa Schwarzkopf, Lars Schwettmann, Thomas Ruhnke, Franziska Trudzinski, Michael Kreuter, Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study, Respiratory Research, 10.1186/s12931-021-01857-y, 22, 1, (2021).
- Bryan T. Kelly, Viengneesee Thao, Timothy M. Dempsey, Lindsey R. Sangaralingham, Stephanie R. Payne, Taylor T. Teague, Teng Moua, Nilay D. Shah, Andrew H. Limper, Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications, BMC Pulmonary Medicine, 10.1186/s12890-021-01607-2, 21, 1, (2021).